Analysts Set Palisade Bio, Inc. (NASDAQ:PALI) Price Target at $8.83

Shares of Palisade Bio, Inc. (NASDAQ:PALI) have earned an average recommendation of “Buy” from the nine brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have given a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $8.8333.

PALI has been the subject of several recent research reports. Weiss Ratings cut Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 14th. Oppenheimer set a $7.00 price objective on Palisade Bio in a research report on Tuesday, June 30th. LADENBURG THALM/SH SH raised shares of Palisade Bio to a “strong-buy” rating in a research note on Thursday, June 25th. HC Wainwright reaffirmed a “buy” rating and set a $2.00 price objective on shares of Palisade Bio in a research note on Tuesday, June 30th. Finally, Wolfe Research began coverage on shares of Palisade Bio in a report on Thursday, April 9th. They set an “outperform” rating and a $7.00 target price for the company.

Insider Buying and Selling

In related news, insider Mitchell Lawrence Jones sold 51,880 shares of the firm’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $2.05, for a total transaction of $106,354.00. Following the sale, the insider owned 94,009 shares in the company, valued at approximately $192,718.45. This trade represents a 35.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Robert Jr. Baltera acquired 25,000 shares of the business’s stock in a transaction on Thursday, July 9th. The stock was purchased at an average cost of $1.96 per share, with a total value of $49,000.00. Following the acquisition, the director directly owned 461,904 shares of the company’s stock, valued at $905,331.84. This represents a 5.72% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have bought 125,000 shares of company stock valued at $250,100. Corporate insiders own 0.07% of the company’s stock.

Hedge Funds Weigh In On Palisade Bio

Several institutional investors and hedge funds have recently modified their holdings of the business. Perceptive Advisors LLC purchased a new position in Palisade Bio during the fourth quarter worth approximately $28,318,000. Commodore Capital LP purchased a new stake in shares of Palisade Bio in the fourth quarter valued at approximately $26,896,000. Janus Henderson Group PLC raised its stake in shares of Palisade Bio by 1.4% during the 1st quarter. Janus Henderson Group PLC now owns 10,689,452 shares of the company’s stock worth $18,760,000 after buying an additional 149,118 shares during the period. Octagon Capital Advisors LP raised its stake in shares of Palisade Bio by 7.4% during the 1st quarter. Octagon Capital Advisors LP now owns 10,276,317 shares of the company’s stock worth $17,984,000 after buying an additional 708,419 shares during the period. Finally, RA Capital Management L.P. purchased a new position in shares of Palisade Bio during the 4th quarter valued at approximately $16,742,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Palisade Bio Stock Performance

NASDAQ:PALI opened at $1.90 on Monday. The firm’s fifty day moving average is $1.92 and its two-hundred day moving average is $1.90. The firm has a market cap of $329.80 million, a price-to-earnings ratio of -1.88 and a beta of 1.50. Palisade Bio has a one year low of $0.53 and a one year high of $2.85.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). As a group, equities research analysts predict that Palisade Bio will post -0.25 earnings per share for the current fiscal year.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.